Claudio Martín

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

Luis Paz‐Ares, Tudor–Eliade Ciuleanu, Manuel Cobo et al. · The Lancet Oncology · 2021 · 1.4K citations

Medicine, Oncology, Pharmacology +14

Updated Frequency of EGFR and KRAS Mutations in NonSmall-Cell Lung Cancer in Latin America: The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP)

Óscar Arrieta, Andrés F. Cardona, Claudio Martín et al. · Journal of Thoracic Oncology · 2015 · 195 citations · Full text

Medicine, Genetics, Oncology +11

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update

Martin Reck, Tudor–Eliade Ciuleanu, Manuel Cobo et al. · ESMO Open · 2021 · 188 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer

Patrick M. Forde, Jonathan Spicer, Mariano Provencio et al. · New England Journal of Medicine · 2025 · 160 citations

Medicine, Oncology, Surgery +15

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

Martin Schüler, James Chih‐Hsin Yang, K. Park et al. · Annals of Oncology · 2015 · 132 citations · Full text

Medicine, Oncology, Pharmacology +13